Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical application of IL6 in cancer therapy.
Mulé JJ, Marcus SG, Yang JC, Weber JS, Rosenberg SA. Mulé JJ, et al. Among authors: weber js. Res Immunol. 1992 Sep;143(7):777-9. doi: 10.1016/0923-2494(92)80023-e. Res Immunol. 1992. PMID: 1439156 Clinical Trial. No abstract available.
The development of gene therapy for the treatment of cancer.
Rosenberg SA, Anderson WF, Blaese M, Hwu P, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Ettinghausen SE, et al. Rosenberg SA, et al. Among authors: weber js. Ann Surg. 1993 Oct;218(4):455-63; discussion 463-4. doi: 10.1097/00000658-199310000-00006. Ann Surg. 1993. PMID: 8215637 Free PMC article.
Current developments of immunotherapy in the clinic.
Antonia S, Mulé JJ, Weber JS. Antonia S, et al. Among authors: weber js. Curr Opin Immunol. 2004 Apr;16(2):130-6. doi: 10.1016/j.coi.2004.01.012. Curr Opin Immunol. 2004. PMID: 15023403 Review.
Translation of cancer immunotherapies.
Mulé JJ, Weber JS. Mulé JJ, et al. Among authors: weber js. Nat Med. 2004 Nov;10(11):1153; author reply 1153-4. doi: 10.1038/nm1104-1153a. Nat Med. 2004. PMID: 15516900 No abstract available.
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.
Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ. Weber J, et al. Clin Cancer Res. 2009 Sep 1;15(17):5591-8. doi: 10.1158/1078-0432.CCR-09-1024. Epub 2009 Aug 11. Clin Cancer Res. 2009. PMID: 19671877 Clinical Trial.
5,226 results